Corvus Pharmaceuticals Inc (NAS:CRVS)
$ 4.9 0.35 (7.69%) Market Cap: 314.86 Mil Enterprise Value: 273.56 Mil PE Ratio: 0 PB Ratio: 24.75 GF Score: 37/100

Corvus Pharmaceuticals Inc at Credit Suisse Healthcare Conference - Scottsdale Transcript

Nov 12, 2019 / 09:25PM GMT
Release Date Price: $2.91 (-9.35%)
Evan David Seigerman;dit Suisse AG
CrÃ;Research Division - VP & Senior Equity Research Analyst

© -

My name is Evan Seigerman. As many of you know, I'm the senior large cap biotechnology analyst here at Crédit Suisse and it's my pleasure to introduce Corvus. And from Corvus, we have the Chief Medical Officer, Dr. Mehrdad Mobasher.

Mehrdad Mobasher
Corvus Pharmaceuticals, Inc. - VP & Chief Medical Officer

Thank you for the introduction. Thanks for having us here and being here, those who are on the line. So we'll get started and apologies for the little delay that we had.

This is our forward-looking statement. It's public. I'm not going to spend any time on it. I just thought I will spend a minute and introduce our team. Dr. Richard Miller is our CEO. He is a hematologist-oncologist. And you can see that himself and the list of our -- my other colleagues at Corvus, they have all been key in development of some of the new novel treatments in hematology and oncology. And my colleague Leiv is here. He is our CFO and will

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot